| ORIGINAL ARTICLE |
|
| Year : 2020 | Volume
: 16
| Issue : 8 | Page : 138-143 |
|
|
A retrospective evaluation of geriatric patients with gastric cancer receiving systemic chemotherapy
Ali Murat Tatli1, Zuhat Urakci2, Didem Tastekin3, Dogan Koca4, Sema Sezgin Goksu1, Ummugul Uyeturk5, Mehmet Ali Kaplan2, Hasan Senol Coskun1
1 Department of Medical Oncology, Akdeniz University, Antalya, Turkey
2 Department of Medical Oncology, Dicle University, Diyarbakir, Turkey
3 Department of Medical Oncology, Istanbul University, Istanbul, Turkey
4 Department of Medical Oncology, Bahcesehir University VM Medicalpark Hospital, Kocaeli, Turkey
5 Department of Medical Oncology, Bolu Abant Izzet Baysal University, Bolu, Turkey
Correspondence Address:
Ali Murat Tatli
Department of Medical Oncology, Akdeniz University, Antalya
Turkey
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jcrt.JCRT_563_18
|
|
|
Background: The most common age at which gastric cancer is diagnosed is 70 years, and the majority of patients diagnosed are at the metastatic stage. However, although gastric cancer is a geriatric disease, there is no suggestion to discriminate treatment for the general geriatric patient population. Here, we evaluated patients receiving palliative chemotherapy for gastric cancer owing to advanced age.
Patients and Methods: Multicenter data of geriatric patients receiving palliative chemotherapy because of metastatic gastric cancer were retrospectively reviewed.
Results: In total, 262 geriatric patients with gastric cancer were included in the study. Of these, 167 patients, including 134 (51.8%) patients with metastasis at diagnosis and 33 patients with relapse after surgery, were evaluated for palliative therapy. Chemotherapy was started in 87 (52.1%) of 167 patients. The overall median survival of the patients receiving chemotherapy was 9.3 months. There was no difference in overall survival (OS) between patients aged >70 and <70 years. However, a significant difference was detected in OS of patients depending on their Eastern Cooperative Oncology Group (ECOG) performance status (PS) before treatment; survival was 15 months in the group with PS 0–1 and 7 months in the group with PS ≥2.
Conclusion: Advanced age chemotherapy receiving rates in patients with metastatic gastric cancer is decreasing. Survival is not associated with age, but pretreatment ECOG PS is important. Therefore, ECOG PS and comorbidities should be evaluated in detail, and combination therapies could contribute to patient survival.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
